Abstract
A double-blind, placebo-controlled study was performed in 55 male patients with recurrent herpes simplex genitalis. The 29 patients who received topical arabinosyladenine monophosphate (ara-AMP) showed no significant difference in viral shedding, duration of pain, healing time or development of new lesions as compared to 26 placebo-treated patients. Ara-AMP was well-tolerated when topically applied. Serum neutralizing antibody titers did not change significantly during the acute and convalescent periods of the patient's recurrent HSG attacks. We conclude that ara-AMP, when applied topically as a 10% gel five times a day within 24 h of onset of recurrent HSG, does not influence the virologic and clinical evolution of the recurrent episode.
Original language | English |
---|---|
Pages (from-to) | 283-290 |
Number of pages | 8 |
Journal | Antiviral Research |
Volume | 2 |
Issue number | 5 |
DOIs | |
State | Published - Oct 1982 |
Externally published | Yes |
Keywords
- arabinosyladenine monophosphate
- double-blind, placebo-controlled study
- genital herpes